PCMI
CPRX

Paradigm Capital Management Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

Paradigm Capital Management Inc’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$77K – 160
2019
Q2 		$77K Buy
+20,000
New +$86.4K 0.01% 160

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Paradigm Capital Management Inc's CPRX Position: Q3 2019 in Review

Paradigm Capital Management Inc sold out of Catalyst Pharmaceutical (CPRX) in Q3 2019, closing a stake of 20,000 shares — an estimated $77K sold.

Paradigm Capital Management Inc first reported a position in CPRX in Q2 2019 and held it in 1 quarter. The position peaked at $77K in Q2 2019. 117 funds tracked by Wall St. Rank hold CPRX as of Q3 2019.

  • Paradigm Capital Management Inc reported no remaining Catalyst Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Paradigm Capital Management Inc sold 20,000 Catalyst Pharmaceutical shares in Q3 2019, an estimated $77K.
  • Paradigm Capital Management Inc first reported a position in Catalyst Pharmaceutical in Q2 2019 and held it in 1 quarter.
  • Paradigm Capital Management Inc's Catalyst Pharmaceutical position peaked at $77K in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2019.

Based on Paradigm Capital Management Inc's 13F filing for Q3 2019, filed 7 Nov 2019.